ClinicalTrials.gg
Not yet recruitingNCT07085715PAN-TESTATEUpdated Jul 25, 2025

Pan-Viral Screening and Linkage to Care Among GBMSM and Trans Women in Spain

An observational study in HIV, Hepatitis B and Hepatitis C, sponsored by Fundació Institut Germans Trias i Pujol. Not yet recruiting. Open to male participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-07-25.

Sponsored by Fundació Institut Germans Trias i Pujol · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Other
Time perspective
Prospective
Enrollment
500
Ages
18 Years and older
Sex
Male
01

Study summary

The World Health Organization (WHO) aims to eliminate viral hepatitis as a public health threat by 2030, with major reductions in hepatitis B and C incidence and mortality. However, hepatitis C virus (HCV) transmission has increased among gay, bisexual, and other men who have sex with men (GBMSM), especially those living with HIV. Practices such as chemsex, particularly involving injection drug use, have contributed to this rise. Hepatitis B virus (HBV) also remains a public health challenge due to the potential for chronic infection and severe liver damage. Hepatitis D virus (HDV), which requires HBV co-infection, further complicates clinical management.

This study aims to design, implement, and evaluate an online self-sampling testing strategy to enhance pan-viral testing (HBV, HCV, HDV, HIV) and improve linkage to care among GBMSM and transgender women (TW) in Spain.

The intervention will involve self-collected dried blood spot (DBS) samples for testing HBV surface antigen (HBsAg), HIV antibodies, and HCV RNA. Individuals testing positive for HBsAg will undergo further testing for HBV DNA and HDV infection. Those lacking protective levels of HBV antibodies will be referred for vaccination or revaccination.

The study will also assess the number of HIV-positive individuals who acquired the infection while waiting for access to PrEP, identifying missed prevention opportunities.

This non-randomized, single-arm, prospective national study will recruit adult GBMSM and TW through PrEP services, dating apps, NGOs, social media, and community outreach. Participants will complete an online risk assessment (using the HCV-MOSAIC algorithm) and receive self-sampling kits with instructions, lancets, Whatman cards, and prepaid envelopes. Results will be provided online, and those testing positive will be linked to confirmatory diagnosis and care.

Outcomes include estimates of HIV, HBV, HCV, and HDV prevalence; effectiveness of linkage to care; acceptability and usability of the intervention; and validation of DBS for HBsAg detection.

This study will provide critical evidence on the effectiveness of online self-sampling strategies for viral hepatitis and HIV among GBMSM and TW, supporting Spain's public health goals for prevention, early diagnosis, and linkage to care.

Read the detailed description

Background: The World Health Organization (WHO) aims to eliminate viral hepatitis as a public health threat by 2030, targeting significant reductions in incidence and mortality for hepatitis B and C. Despite these goals, hepatitis C virus (HCV) transmission and acute infection rates have risen among gay, bisexual, and other men who have sex with men (GBMSM), especially those with HIV. Chemsex, particularly involving drug injection, is a notable risk factor. Hepatitis B virus (HBV) also poses a significant public health challenge, with chronic hepatitis B leading to severe liver damage in a significant portion of those infected. Hepatitis D virus (HDV), which requires HBV co-infection, adds further complexity to the management of viral hepatitis. Integrating evidence-based interventions for HIV and STI prevention, including effective screening and linkage to care, is urgently needed.

Objectives: This study aims to design, implement, and evaluate an online self-sampling testing strategy to enhance pan-viral testing (HBV, HCV, HDV, HIV) and improve linkage to care among GBMSM and transgender women (TW) in Spain. Specific objectives include:

  1. Designing and implementing an online self-sampling pilot intervention for HBV, HIV, and viremic HCV detection using dried blood spot (DBS) samples, and following up on positive HBV cases for HDV co-infection.
  2. Analyzing the intervention's effectiveness in reaching and identifying undiagnosed infections among GBMSM and TW not recently tested for HIV and viral hepatitis.
  3. Identifying individuals who have not vaccine-induced protective levels against HBV and linking them to vaccination (or revaccination) services.
  4. Evaluating the intervention's acceptability among GBMSM and TW inSpain.
  5. To identify the number of individuals with HIV infection while they are waiting PrEP (missed opportunities to prevent HIV infection) A secondary objective is to validate DBS samples for detecting HBV surface antigen (HBsAg).

Methods: This non-randomized single-arm prospective and national study will recruit adult GBMSM and TW through PrEP services, social media, gay dating apps, NGOs, and outreach interventions. Participants will complete a risk assessment using the HCV-MOSAIC algorithm, and eligible individuals will receive a self-sampling kit for HBV, HCV, and HIV testing. The kits will include instructions, a lancet, a Whatman card for DBS collection, and a pre-paid return envelope. Samples will be analyzed by a reference laboratory for HBsAg, HIV antibodies, and HCV RNA. Participants will receive their results online, with follow-up for those testing positive to confirm diagnoses and linkage to care. Those who test positive for HBsAg will be further tested for other tests, including HBV DNA, and HDV infection.

Expected Outcomes: The study will estimate HBV, HDV, HCV, and HIV prevalences, assess linkage to care and treatment outcomes, and evaluate the acceptability and usability of the self-sampling intervention. Additionally, the validation of DBS for HBsAg detection will provide crucial data for future screening strategies.

Conclusion: This study will provide valuable insights into the effectiveness of self-sampling interventions for viral hepatitis and HIV among GBMSM and TW, contributing to public health efforts to reduce the burden of these infections in Spain. To identify the number of individuals with HIV infection while they are waiting PrEP (missed opportunities to prevent HIV infection)

02

Conditions studied

  • HIV
  • Hepatitis B
  • Hepatitis C

Keywords

  • Self-sampling
  • Screening
03

In context

Hepatitis B

1,048 studies on the registry are indexed under Hepatitis B; 141 are open to participants now.

This study's planned enrollment of 500 is above the median of 365 across 251 observational studies indexed under Hepatitis B.

Browse Hepatitis B studies →

Lead sponsor

Fundació Institut Germans Trias i Pujol is the lead sponsor of 25 studies on the registry; 9 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Male
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

Gay, bisexual, and other men who have sex with men (GBMSM) and transgender women residing in Spain

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Men self-reporting being gay, bisexual, and other men who have sex with men (GBMSM) or transgender women
  • 18 years old or older
  • Residing in Spain
  • Accepting to participate and signing the
  • Including those who are in PrEP or waiting access to PrEP; regardless of their status (HIV-negative or HIV-positive), and considered at risk for acute infection using the MOSAIC validated algorithm (score of 2 or higher).

Exclusion criteria

Exclusion Criteria:

  • \<18 years old
  • No GBMSM or transgender women
  • Non-residents in Spain
  • No signing the
  • Not considered at risk for acute infection using the MOSAIC validated algorithm (score lower than 2).
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Observational model
Other
Time perspective
Prospective
Enrollment
500 participants (estimated)
Patient registry
No

Interventions

  • Diagnostic testOnline self-sampling testing strategy to enhance pan-viral testing (HBV, HCV, HIV)

    The TESTATE website (https://testate.org/) will be expanded to include the offer of free HBV/HCV/HIV self-sampling kit. Users will log in and complete a sociodemographic, behavioral and hepB vaccination survey, which will include the HCVMOSAIC questionnaire. Users identified at HCV risk will be sent a DBS collection kit by post to detect HCV RNA, HBsAg and HIV Ab. Participants will self-collect the DBS sample by finger prick at home and send them to the laboratory by post. The results will be delivered online. All participants who return samples will receive an acceptance survey by email. All participants recruited into the study will be provided with online information about the study and given the opportunity to ask questions and clarify queries to the field coordinator by email or phone.

06

What researchers measure

Primary outcomes

  1. Reach and Identification of Undiagnosed HBV/HCV/HIV Infections

    Number of GBMSM and TW reached by the intervention Number of undiagnosed HBV, HCV, and HIV infections identified among participants

    Time frame: October 2025 - September 2026

  2. Linkage to Care_1

    • Number and proportion of participants with positive results linked to appropriate care and follow-up.

    Time frame: October 2025 - September 2026

  3. Linkage to care_2

    • Follow-up and cure rates for HCV infection among participants with positive results.

    Time frame: October 2025 - September 2026

  4. Linkage to care_3

    • Number of individuals identified as not vaccinated against hepatitis B and linked to vaccination services.

    Time frame: October 2025 - September 2026

  5. Intervention Usability and Acceptability_1

    • Number of participants consulting their results.

    Time frame: October 2025 - September 2026

  6. Intervention Usability and Acceptability_2

    • Participant satisfaction with the intervention, perceived advantages and disadvantages, suggestions for improvement..

    Time frame: October 2025 - September 2026

  7. Intervention Usability and Acceptability_3

    • Percentage of participants repeating HIV/HBV/HCV screening.

    Time frame: October 2025 - September 2026

Secondary outcomes

  1. Effectiveness of DBS Screening_1

    Proportion of participants with confirmed positive results for HBV, HCV, and HIV using DBS self-samples.

    Time frame: October 2025 - September 2026

  2. Effectiveness of DBS Screening_2

    Validation metrics for DBS samples in detecting HBsAg, including the area under the ROC curve and the 95% confidence interval.

    Time frame: October 2025 - September 2026

  3. Missed Opportunities for HIV Prevention

    • Number of participants on the waiting list for PrEP who are diagnosed with HIV.

    Time frame: October 2025 - September 2026

  4. Sociodemographic and Risk Behavior Analysis_1

    • Comparison of sociodemographic characteristics and risk behaviors between positive and negative participants.

    Time frame: October 2025 - September 2026

  5. Sociodemographic and Risk Behavior Analysis_2

    • Data disaggregated by gender, migratory status, and sexual orientation.

    Time frame: October 2025 - September 2026

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Oct 2025; primary completion for Sep 2026, 11 months later.

Of 69 non-industry observational studies under Hepatitis B, half reached primary completion within 59 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 126. This study's planned 11 months is below that.

Counting every sponsor, half of 81 studies reached it within 55 months; a quarter within 17 and three quarters within 126.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 8, 2025
First posted
Jul 25, 2025
StartEst.
Oct 2025
Primary completionEst.
Sep 2026
CompletionEst.
Dec 2026
Last update
Jul 25, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 25, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07085715
Lead sponsor
Fundació Institut Germans Trias i Pujol
Responsible party
Sponsor
First posted
Jul 25, 2025
Start date
Oct 2025 (estimated)
Primary completion
Sep 2026 (estimated)
Completion
Dec 2026 (estimated)
Last update
Jul 25, 2025

Study contacts

Cristina Agusti, MSc, PhD
Contact
cagusti@iconcologia.net
+34934978891
Andreu Colom, PhD
Contact
acolom@igtp.cat
Cristina Agusti, MSc, PhD
study director · ico oncologia

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jul 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion